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Abstract
Background: This study aimed to clarify interactions of the pattern-recognition receptor DC-SIGN with cells from
the HIV-infected peripheral blood lymphocyte cultures.
Methods: Cells from control and HIV-infected peripheral blood lymphocyte cultures were tested for the surface
expression of DC-SIGN ligands. The DC-SIGN ligand expressing cells were analyzed for the role of DC-SIGN-ligand
interaction in their functionality.
Results: In the vast majority of experiments HIV-infected lymphocytes did not express detectable DC-SIGN ligands
on their cell surfaces. In contrast, non-infected cells, carrying NK-specific marker CD56, expressed cell surface DC-SIGN
ligands. The weakly polysialylated CD56 was identified as a novel DC-SIGN ligand. The treatment of DC-SIGN expressing
dendritic cells with anti-DC-SIGN antibodies increased the anti-dendritic cell cytotoxicity of CD56pos cells. The treatment
of CD56pos cells with a peptide, blocking the weakly polysialylated CD56-specifc trans-homophilic interactions, inhibited
their anti-dendritic cells cytotoxicity.
Conclusions: The interaction between DC-SIGN and CD56 inhibits homotypic intercellular interactions of CD56pos cells
and protects DC-SIGN expressing dendritic cells against CD56pos cell-mediated cytotoxicity. This finding can have an
impact on the development of approaches to HIV infection and cancer therapy as well as in transplantation medicine.
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Background
Immune tolerance, a state of unresponsiveness of the
immune system to specific immunogens, can be reached
by different mechanisms, including the dysregulation of
dendritic cells (DCs). As antigen presenting cells, DCs
play a central role in effective immune response develop-
ment. Complete dysregulation or depletion of DCs causes
immunodeficiency. Although different stages of HIV and
SIV infections vary in the level of DC dysregulation, the
depletion of DCs from blood stream and from lymph
nodes is characteristic for late stages of these infections
[1–4]. The DC functional deficiency can be the key elem-
ent for AIDS development. However, the mechanisms
causing the HIV infection-associated DC depletion remain
vague. Among other possible factors natural killer (NK)
cells might mediate the DC depletion in HIV infection
similar to their participation in the CD4+ T cell depletion
[5]. HIV infection is associated with the dramatic depletion
of DCs in lymph nodes, the main place of antigen presenta-
tion by the mature DCs (mDCs), expressing full range of
MHC class I and II molecules [6]. At the same time, SIV in-
fection causes accumulation of cytotoxic CD16+ NK cells
(analogues of CD56dimCD16pos ones in human) in lymph
nodes where they are not normally present, in contrast to
the much less cytotoxic cytokine secreting CD56hiCD16neg
NK cells that are normal for lymph nodes [7–9].
DC-SIGN (Dendritic Cell-Specific Intercellular adhesion
molecule-3-Grabbing Non-integrin; CD209) is a C-type
lectin receptor present on macrophages and dendritic
cells. DC-SIGN interacts with high-mannose oligosaccha-
rides conjugated to HIV-1 envelope glycoprotein gp120.
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This interaction can initiate the temporal internalization
of HIV virions and increase the efficacy of HIV transmis-
sion [10]. HIV-1 infected cells can express gp120 on their
cell surfaces where gp120 can be recognized by DC-
SIGN-expressing dendritic cells. The ability of DC-SIGN
expressing cells to enhance HIV infection was originally
found for cells from placenta [11]. These cells appeared to
be DCs forming tight interaction with natural killer (NK)
cells [12–14]. In normal decidua, DC-SIGNpos immature
dendritic cells (iDCs) form one of the most presented cell
populations whereas spontaneous abortions are associated
with the decreased number of these cells [15, 16]. As a
part of pregnancy immune tolerance mechanisms decidual
NKs seem to inhibit iDCs maturation and prevent mature
DCs from migrating to the lymphoid tissues [17, 18]. The
killing of the maturing DCs in placenta occurs despite the
maturation-associated growth of the cell surface density of
major histocompatibility complex (MHC) class I, a known
factor of NK cytotoxicity inhibition. On the other hand,
the maturing DCs moderately decrease the surface expres-
sion of DC-SIGN [19]. The role of DC-SIGN and its
ligands (including the HIV associated ones) in the inhib-
ition of NK cytotoxicity remains unclear.
In this study interactions of DC-SIGN with HIV-
infected peripheral blood lymphocytes (PBLs) were ana-
lyzed. The cell surface DC-SIGN ligand (DC-SIGN-L)
expression was found as a rare event for HIV-1 infected
CD4 lymphocytes. In contrast, non-infected CD56pos cells
were mostly found as DC-SIGN-Lpos ones. The weakly
polysialylated CD56 was identified as a novel ligand
for DC-SIGN that can regulate anti-DC cytotoxicity of
CD56pos cells. These findings give a better understanding
of HIV-infection pathogenesis and pregnancy-associated
immune tolerance.
Results
DC-SIGN rarely binds to HIV-1 infected cells
To study the interactions between HIV-1 infected cells
and DC-SIGN, donor PBLs were activated, infected with
HIV-1 and stained with a soluble DC-SIGN-Fc chimera.
Infected PBLs were expected to bind soluble DC-SIGN
due to the cell surface expression of HIV-1 envelope
glycoprotein gp120. However, in the vast majority of
experiments HIV-1 infected (viral core protein p24 posi-
tive (p24pos)) cells did not express DC-SIGN-L (Fig. 1a).
Nevertheless, for some donors the p24highDC-SIGN-Lneg
and p24lowDC-SIGN-Ldim cell populations were found
(Fig. 1b). When the rare donors infected cells were
stained for CD4, an additional population of DC-SIGN-
LposCD4pos cells was detected (Fig. 1c). Thus, the used
culturing conditions either stimulate the gp120 shedding
from the surface of infected cells or the HIV budding
occurs inside cells and gp120 is simply not present on
the infected cell surface. The accumulation of p24 in the
p24highDC-SIGN-Lneg cells supports rather the intracel-
lular budding option.
Surprisingly, a population of non-infected cells gave a
high signal specific for DC-SIGN-L (Fig. 1a and c). From
this point the focus of research shifted away from HIV-1
infected cells to the characterization of this p24negDC-
SIGN-Lpos population.
DC-SIGN binds to CD56+ cells
The phenotypic analysis identified the p24negDC-SIGN-Lpos
cells as CD3+/−CD56 +CD11b +CD16 +CCR5-CXCR4-
CD161+/−CD57+/–ones. The CD56 or NCAM (Neural
Cell Adhesion Molecule; an NK-and neuron-specific anti-
gen) cell surface expression suggests that these cells belong
to a heterogenic population of NK and NKT cells (NK (T)
cells) that according to the phenotype and culturing
conditions should have some features of non-MHC-
restricted cytokine induced killers [20, 21]. In human
blood, two main subsets of NK cells have been described,
cytolytic CD56dimCD16pos and non-cytolytic cytokine
secreting CD56bright (hi)CD16neg subsets, of which the
CD56dimCD16pos subset predominates [9]. CD56hiCD16neg
subset did not bind DC-SIGN (Fig. 2a). This result can
reflect the known difference in the level of CD56 polysialy-
lation found for cytotoxic and non-cytotoxic NK subsets
[22]. Notably, the activation of PBLs caused depletion of
the CD56hiCD16neg NK subset and increased the CD56
surface expression that clearly correlated with the level of
DC-SIGN-L expression (Fig. 2a, b). The interaction be-
tween the soluble DC-SIGN and CD56pos cells was lectin
specific, since it could be inhibited by the polycarbohydrate
mannan and the calcium-chelator EGTA (Fig. 2c).
Lewis (Le) carbohydrates are specific DC-SIGN ligands
[23]. The LeX (Gal1-b-4 [Fuc1-α-3] GlcNAc)-containing
structures (LeX or LeY) have also been found on NCAM
[24]. To clarify the expression of LeX-like structures, the
activated PBLs were stained with antibodies to CD56,
LeY and LeX carbohydrates. Both CD56pos and CD56neg
cells showed no difference in the level of LeX expression.
However, CD56pos cells had the higher LeY expression
(Fig. 2d).
Weakly-polysialylated CD56 is a novel DC-SIGN ligand
The obtained data strongly suggest that CD56pos acti-
vated PBLs express a DC-SIGN ligand on their cell
surface. To clarify mechanisms mediating the correlation
between the levels of CD56 and DC-SIGN-L expression
(Fig. 2b), CD56 from cell-lysates was captured with the
presorbed specific antibodies and the interaction with
soluble DC-SIGN was determined in ELISA. The cap-
tured CD56 interacted with soluble DC-SIGN in a lectin-
specific manner (Fig. 3a). The similar approach showed
that CD56 is associated with LeY carbohydrates (Fig. 3b).
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To further clarify relationships between DC-SIGN and
CD56, the analysis of cell surface-associated CD56 and
DC-SIGN-L was performed using immuneprecipitation
followed by immunoblot. The immunoprecipitated DC-
SIGN ligands and CD56 from the cells, pretreated with
biotin, were analyzed in immunoblot with streptavidin
(Fig. 3c, left panel). The immunoprecipitated cell surface
CD56 was analyzed in immunoblot with DC-SIGN-Fc
and anti-CD56 antibodies (Fig. 3c, right panel). The
results of the immunoblots indicate that a 180 kDa DC-
SIGN ligand is present both in the lane of cell surface




Fig. 1 DC-SIGN binding to cells in HIV-1 infected cultures. a The typical dotplot of HIV-1-infected and non-infected control and PBLs stained for
DC-SIGN-L and HIV-1 core protein p24. b The density plot of rare HIV-1 infected and non-infected PBLs stained as described above in Fig. a. c The
dotplot of HIV-1 infected and non-infected PBL cultures stained for CD4 and DC-SIGN-L
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(Fig. 3c). In latter case the DC-SIGN-specific signal
corresponds to the CD56-180 isoform of CD56, having
several isoforms different in their protein molecular
weight [25]. The CD56 specific signal in both immuno-
blots revealed a smeared band corresponding to 175–
200 kDa characteristic for CD56 (Fig. 3c) [25]. This
175–200 kDa band is known to reflect the length differ-
ence of negatively charged polysialic acid (PSA) conju-
gated to the 180 kDa protein backbone of CD56 [25].




Fig. 2 DC-SIGN-Fc binds in a C-type lectin-specific manner to CD56pos cells expressing Lewis Y carbohydrates. a The dot plots of activated and
freshly isolated PBLs stained for DC-SIGN-L, CD56 and CD16. b The dot plots of activated PBLs stained for CD56 and DC-SIGN-L. c The DC-SIGN-Fc
binding to CD56pos cells was analyzed in the absence and in the presence of DC-SIGN inhibitors: mannan (2 mg/ml), EGTA (10 mM). Human
serum (Hum. Serum) was used as a negative control for unspecific human Fc fragment bindings. The experiment was performed in triplicates and
error bars represent ± SD of triplicates. d Histograms of CD56pos (clear plots) and CD56neg (grey plots) activated PBLs stained for -Lewis X (left)
and Lewis Y (right) carbohydrates surface expression with specific antibodies




Fig. 3 Identification of non-polysialilated CD56 as a novel ligand of DC-SIGN. a The presorbed anti-CD56 or isotype (Iso) control antibodies were incubated
with PBL lysates. DC-SIGN-Fc (DC) binding to the captured CD56 alone or in the presence of inhibitors (EGTA and mannan, E-M) was assessed. ICAM-3-Fc
(ICAM) was used as a negative control. b The binding of anti-Lewis sugars antibodies (Le) to the captured CD56 was assessed. Negative control (N.C.)
was performed without anti-Lewis antibodies. a and b experiments were performed in triplicates and error bars represent ± SD of triplicates. c The immuno-
precipitated DC-SIGN ligands (sDC) and CD56 (a-CD56) from activated PBLs, pretreated with biotin, were analyzed in immunoblot with streptavidin, left
panel. The immunoprecipitated cell surface CD56 was analyzed in immunoblot with DC-SIGN-Fc and anti-CD56 antibodies, right panel. The arrow points
out a common for the two immunoblots band. d Results of anion exchange (AEX) chromatography separation of immunoprecipitated CD56 from the acti-
vated PBL lysate. Fractions I and II were collected. e The fraction I (black bars) and fraction II (white bars) obtained in the AEX experiment were directly
sorbed of ELISA plates and analyzed for binding anti-CD56 antibodies and DC-SIGN-Fc with or without of inhibiting mannan/EGTA (Man/EGTA) mixture
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PSA-related nature of the smeary CD56 band (data not
shown). These results confirm that the cell surface
CD56-180 is a pool of 180 kDa protein molecules that
differ in the length of the attached PSAs, forming the
wide smeared band [25]. However, the results also spe-
cify that DC-SIGN interacts on the cell surface with the
non-or slightly polysialylated variants of CD56-180,
forming a narrow band in the area corresponding to
180 kDa protein on immunoblot.
The following anion-exchange HPLC of CD56 from
cell surface showed the presence of two main protein
containing fractions different in their column binding
properties (Fig. 3d). The retention of fraction II on the
column suggests that compounds from this fraction are
highly negatively charged in contrast to the fraction I that
moved through the column without retention. CD56 was
detected equally by ELISA in both fractions but the DC-
SIGN lectin-specific interaction with fraction I was signifi-
cantly higher (Fig. 3e), which supports the hypothesis that
DC-SIGN interacts with the weakly polysialylated form of
CD56.
DC-SIGN affects the anti-DC cytotoxicity of CD56pos
cells that depends on weakly polysialylated-CD56
trans-homophilic interactions
The functional DC-SIGN–CD56 interaction suggests a
tight interaction between DCs and NK cells. Indeed DCs
and the CD56pos cells formed tight cellular complexes.
Preincubation of dendritic cells with anti-DC-SIGN anti-
bodies or mannan did not change the complex forma-
tion (Fig. 4a). This suggests that the interaction of CD56
with DC-SIGN rather regulates cell activities than plays
a substantial role in adhesion between NK and dendritic
cells, mediated by multiple other adhesion molecules.
NK cells are known to kill cells that do not express
MHC class I on their surface and the mechanism of this
killing is well described. NK cells also can kill MHC
class I expressing cells but the mechanism of this killing
remains unclear. CD56 does not play a role in the NK
cell mediated lysis of K562 cells, a model target cell line
expressing no MHC class I [26]. In the light of the de-
scribed above results this suggests that DC-SIGN also
does not play a substantial role in the killing of K562 cells.
To clarify the role of DC-SIGN for K562 cells and DCs
cytotoxic death, CD56pos cells were used in the cytotox-
icity test with target K562 cells and DCs in different ratios
of target/effector (T/E) cells. The killing of K562 cells was
detected even at T/E ratio of 5 to 1. The DC-SIGN
expression did not significantly (with a trend to increase
for DC-SIGN-K562 cells) change the lysis of K562 cells
(Fig. 4b). However the killing of DCs by the same CD56pos
cells was detected only at 1 to 5 T/E ratio. These results
strongly suggest deeply different mechanisms of the K562
and DCs killing where the killing of DCs needs a certain
cooperation of CD56pos cells. To further clarify the role of
DC-SIGN in the CD56pos cell cytotoxicity of DCs, the
latter, pretreated with anti-DC-SIGN antibodies, were
used in the cytotoxicity experiments. These experiments
revealed that the inhibition of DC-SIGN lectin activity by
antibodies significantly increased the killing of mDCs
(Fig. 4c).
The non-polysialylated (non-PSA) NCAM (CD56) forms
both cis-and trans-homophilic (CD56-CD56) interactions
whereas homotypic intercellular interactions between
NK cells are required for certain types of NK cytotoxicity
[27–29]. However, the functionality of CD56 surface ex-
pression on NK cells remains unclear. To investigate the
role of the CD56-mediated homophilic interactions in the
anti-DC cytotoxicity of CD56pos cells, the C3d dendro-
meric peptide, blocking the trans-homophilic NCAM
interaction, was used [30]. Pre-incubation of CD56pos cells
with the C3d peptide significantly decreased the killing
of both iDC and mDCs in a dose-dependent manner
(Fig. 4d).
Altogether these results suggest that CD56 and DC-
SIGN do not play a significant role in the MHC class I
negative target cell killing. However, these molecules seem
to play very important role in the fate of DCs interacting
with CD56pos cells.
Discussion
HIV-1 infection is characterized by the high level of im-
mune activation. The current regimens of antiretroviral
therapy are unable to inhibit this antigen presenting cell-
driven viral-induced immune hyperactivation [31]. On the
other hand, the presence of host factors that inhibit this
immune activation can be assumed. The immune activa-
tion seems to mediate the optimal conditions for HIV
propagation in host. This has its reflection in the activa-
tion of non-infected donor PBLs as a preparation step for
HIV infection in vitro. The protocol of PBLs activation for
HIV infection resembles the one for induction of cytokine
induced killer cells, used in immune therapy of tumors
[21]. Therefore, it was not a surprise that on the day 10–
14 of HIV-1 infection in the presence of IL-2 a substantial
number of cells, carrying specific NK marker CD56, was
detected. The surprise was that those CD56pos were often
the main binders of soluble DC-SIGN, used originally to
detect the surface expression of HIV-1 envelop gp120 on
infected PBLs. The rare finding of DC-SIGN-Lpos cells
among CD4 HIV-infected PBLs reflects rather the rare
budding HIV-1 virions from the cell surface. The finding
of DC-SIGN-Lnegp24high infected cells in the majority of
the studied donor lymphocytes suggests accumulation of
viral particles inside the infected cells before their release.
This supports the findings that HIV virions are mostly re-
leased using exocytosis from intracellular multivesicular
bodies wherein they bud [32]. This strategy allows virus to
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prevent the recognition of infected cells by immune
system.
Non- or slightly polysialylated CD56 was found as a
novel DC-SIGN ligand on the surface of activated CD56pos
cells. NCAM is known to be present in polysialylated and
non-polysialylated forms strikingly different in their func-
tions [27]. Among the potential DC-SIGN ligands the
LeY oligosaccharides were identified as associated with
CD56, which confirms the described presence of NCAM-





Fig. 4 NK–mediated cytotoxicity of DC but not K562 depends on both DC-SIGN and CD56 trans-homophilic interaction. a The dotplots of isolated
CD56pos cells (NK), DC-SIGN expressing DCs and their co-culture. Preincubation of DCs with anti-DC-SIGN antibodies or mannan did not change
the picture; b The CD56pos cell cytotoxicity of K562, DC-SIGN-expressing K562, iDCs and mDCs taken in different effector/target ratios. c Pre-incubation
of DCs with DC-SIGN lectin inhibiting antibodies (AZD1/D2) increases the CD56 cytotoxicity of DC. Error bars represent ± SD of experiment
quadruplicates. d The trans-homophilic interaction blocking peptide C3d inhibits the CD56pos cell cytotoxicity of DCs. Error bars represent ± SD of
experiment quadruplicates. In experiments c and d ratio DC:NK was 1:8. The results are representative from several experiments
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medium-length PSA chains on CD56 are characteris-
tic for active cytotoxic NK cells whereas cytotoxically
inactive NK cells express long PSA, suggesting differ-
ent glycosylation machinery in these two NK popula-
tions [22]. The obtained phenotyping data suggest that
the found CD56posDC-SIGN-Lpos cells resemble the cyto-
toxic CD56dimCD16pos subset of NK cells whereas non-
cytotoxic CD56hiCD16neg cells, more characteristic for
lymph nodes, do not bind DC-SIGN. Thus, DC-SIGN–
CD56 interaction plays a role mostly for cytotoxic NK (T)
cells. Of interest, in the presence of the transforming
growth factor-β and IL-15 (normal in human decidua)
CD56dimCD16pos NK cells convert into CD56dimCD16neg
NK cells with properties similar to decidual NK cells [33].
The inhibition of DC-SIGN lectin activity with specific
antibodies increased the anti-DC cytotoxicity of CD56pos
cells, which suggests a DC-SIGN inhibitory role in the
regulation of the CD56pos cells cytotoxicity when these
cells tightly interact with DCs. On the other hand, the
absence of the DC-SIGN protective effect for K562 cells,
having no MHC class I expression, suggests that the DC-
SIGN-mediated protective effect is significant mostly for
MHC class I expressing target cells. These data are in line
with the findings that CD56 on NK cells does not mediate
the killing of K562 cells but the killing of more complex,
in terms of MHC expression, targets [26].
The polysialylated molecules are highly negatively
charged and electrostatically repel each other on the same
and neighbor cells. In contrast to polysialylated CD56, the
tips of non-or slightly polysialylated CD56 molecules form
bonds with CD56 on the same and neighboring neurons
(cis-and trans-homophilic interactions, respectively). The
cis-homophilic bonds create a kind of cell surface shield
that can be used for intercellular contacts and protection
of underlying structures (including the NCAM conjugated
LeX-like structures) against unspecific bindings [24, 27].
This can explain why anti-LeY antibodies, in contrast to
soluble DC-SIGN, interacted with a relatively small part of
CD56pos cells from the activated PBL cultures.
NK cytotoxicity is highly controlled by intercellular in-
teractions including homotypic (NK-NK) ones [28, 29, 34].
The inhibition of anti-DC cytotoxicity of CD56pos cells in
the presence of the C3d peptide, inhibiting trans-homo-
philic CD56 interactions, suggests the functional role of
CD56 homophilic bonds in the MHC class I independent
CD56pos cytotoxicity. The DC-SIGN-CD56 interaction
sterically excludes the interacting CD56 molecule from
other interactions including the trans-homophilic ones
mediating cytotoxicity, which decreases anti-DC cytotox-
icity of CD56pos cells.
The mimicry, simulating the normal host structures or
functions, is a well-known survival strategy of microbial
pathogens that allows them to avoid or to suppress the
host immune system response and co-exist with the
host. The immunoglobulin-like receptor CD56 is heavily
N-glycosylated, has the five loops protein structure and
can bind DC-SIGN, which strikingly resembles the struc-
ture and properties of HIV-1 envelope gp120. Thus, the
host immune system might take the HIV infected cells
expressing envelope gp120 for the activated CD56pos cells.
Moreover, shedded gp120 might inhibit DC-SIGN interac-
tions with CD56 and induce DC depletion.
Conclusions
This study demonstrates that the DC-SIGN expression
is one of the DC maturation state factors that can define
the level of NK (T) cell cooperation-dependent cytotox-
icity. These findings suggest DC-SIGN ligands as new
immune tolerogenic compounds that might be applied
for the NK (T)-mediated regulation of both the number
of DCs and the level of DCs maturation. The used in this
study approaches on the inhibition of CD56-dependent
cytotoxicity allow targeting MHC class I independent
cytotoxicity of NK (T) cells. Altogether these results can
be useful in development of new approaches to the non-
MHC-restricted cytokine induced killer cells-based ther-
apies, the maintenance of pregnancy, transplant rejection
inhibition and HIV infection treatment.
Materials and methods
Antibodies
The following monoclonal antibodies were used: AZN-D1
and-D2 (DC-SIGN) [12], UCHT1 (CD3), 3G8 (CD16),
L307.4 (CD80), 2331 (CD86), G46-6 (HLA-DR), B159
(mouse IgG1) and NCAM16.2 (mouse Ig2b) (both CD56),
MOPC-21 (IgG1 isotype control), NK-1 (CD57) (all from
BD Pharmingen). Mouse mAbs against Lewis sugar struc-
tures: Lewis X; Lewis Y, and Lewis B were purchased from
Calbiochem. Anti-PSA monoclonal antibody (735) was a
generous gift from Dr. Martina Muhlenhoff.
The used soluble DC-SIGN-Fc chimera consisted of the
extracellular portion of DC-SIGN (aa residues 64–404)
fused at the C terminus to the human IgG1-Fc domain
[35]. DC-SIGN-Fc was produced in Chinese hamster
ovary K1 cells after transfection with the DC-SIGN-Sig-
pIgG1-Fc vector (20 μg). ICAM-3-Fc that contains the
same as Fc fragment as DC-SIGN-Fc or 10 % human sera
were used as a negative control for Fc binding.
The fluorochrome-conjugated monoclonal antibodies
used in flow cytometry were: CD3 (BD-PharMingen),
CD11b (Coulter); DC-SIGN (R&D Systems) CD3, CD4,
CD8, CD56 (all from Beckman Coulter), biotinylated
anti-CD16 CD86, HLA-DR (Both from BD-PharMingen);
PerCP labeled anti-human CD4; anti-mouse IgG and goat
anti-human Fc antibodies (Jackson Immunoresearch Lab.
Inc.).
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Cells
The NK-susceptible K562 (human chronic myelogenous
leukemia) cell line, which lacks HLA class I expression, as
well as K562 expressing DC-SIGN (K562-DC) [12] were
used as a positive control target in cytotoxicity assays. Ficoll
isolated PBL were activated with 5 μg/ml phytohemagglu-
tinin (Sigma) and cultured in RPMI medium containing
10 % fetal calf serum, penicillin (100 units/ml), and strepto-
mycin (100 units/ml) with recombinant interleukin-2 (100
units/ml) (Strathmann Biotech Ag) for 3 days. On day 4
PBLs were washed and cultured in the same culture
medium but without PHA. For HIV infection experiments
HIV-1 (JRCSF) (100 TCID50 per 10
5 cells) was added to the
PBL culture on day 1 after the PHA stimulation. CD56pos-
cells were isolated with anti-human CD56 microbeads
(Miltenyi Biotec GmbH) from the 10–14 days old PBL
cultures. Isolated NK cells were routinely tested for CD56
surface expression. The purified CD56pos cells were cul-
tured in the cell free PBL medium culture for 24 h before
used in the experiments.
Immature and mature DCs were derived from mono-
cytes as described [36]. Briefly, monocytes were isolated
from buffy coats of healthy donors by Ficoll centrifuga-
tion and MACS sorting for CD14+ cells using CD14
microbeads (Miltenyi Biotec GmbH). Isolated monocytes
were cultured for 7 days on RPMI 1640 10 % FCS in the
presence of IL-4 (600 U/ml) and GM-CSF (800 U/ml) to
obtain immature DCs and in the presence of LPS (from
Escherichia coli, Sigma-Aldrich, St Louis, MO, 2 μg/ml)
in the final 2 days to obtain mature DCs. Maturation of
DCs was followed using cell staining for the maturation
markers as CD86 and HLA-DR.
DC-SIGN-Fc cell staining
DC-SIGN-Fc cell staining was performed to find expres-
sion of DC-SIGN ligands on the cell surfaces. PBLs were
incubated with DC-SIGN-Fc for 30 minutes at 37 °C
under saturating conditions (10 μg/ml), washed and sub-
sequently stained with FITC-conjugated goat anti-human
secondary antibodies (Jackson Immunoresearch Lab. Inc.,
West Grove, PA). HIV-infected PBLs were taken for the
analysis on day 8–11 after infection. All procedures were
performed in TSM (20 mM Tris–HCl pH 8.0, 150 mM
NaCl, 1 mM CaCl2, 1 mM MgCl2) buffer containing 2 %
bovine serum albumin (BSA). In DC-SIGN blocking
experiments, DC-SIGN-Fc was preincubated for 10 min at
room temperature either with mannan (50 μg/ml) or
EGTA (10 mM). Signals were acquired on a flow cyt-
ometer (FACSCalibur; BD Biosciences) and analyzed by
CellQuest Software.
ELISA
Samples after anion-exchange chromatography were dir-
ectly coated onto ELISA plates (NUNC maxisorp, Nalge
Nunc Int., Rochester, NY) in 0.2 M sodium carbonate buf-
fer pH 9.2 for overnight at 4 °C followed by incubation in
TSM buffer containing 1 % BSA for 30 min at 37 °C. DC-
SIGN-Fc (ICAM-3-Fc as a negative control) (2 μg/ml) was
added and incubated in TSM 1 % BSA 1 h at room
temperature. Unbound DC-SIGN-Fc was washed away
and the binding was determined using a peroxidase-
conjugated goat anti-human Fc antibody (Jackson Immu-
noresearch Lab. Inc.) that was incubated for 30 min at
room temperature. The analysis of the fractions for the
presence of CD56 was performed with anti-CD56 mAbs
(clone NCAM 16.2, BD Biosciences) as described above
for DC-SIGN. The binding was determined using a
peroxidase-conjugated rabbit anti-mouse IgG2b antibody
(Zymed Laboratories, Inc.).
In the CD56 glycosylation ELISA analysis the anti-CD56
mAbs (clone NCAM 16.2, BD Biosciences, mouse Ig2b)
mAbs were coated (5 μg/ml) and blocked with BSA as
described above. PHA activated PBLs were lysed in NP-40
containing buffer for immuneprecipitation containing
protease inhibitors (100 mln/ml) and then added and re-
moved four times following 30 min incubation at RT with
the coated anti-CD56 mAbs. The captured CD56 was ana-
lyzed with: a) anti-Lewis B, X or Y monoclonal antibodies
(all mouse IgM, 3 μg/ml) following by the incubation with
secondary anti-mouse IgM-peroxidase conjugate (Zymed
Laboratories, Inc.); b) DC-SIGN-Fc as described above.
All ELISA experiments were performed in triplicate and
several times.
Immunoprecipitation and immunoblot analysis
PBLs after stimulation with PHA/IL-2 were cultured for
10–14 days in the presence of IL-2. To isolate cell sur-
face CD56, preincubation of PBLs with anti-CD56 mAb
(clone B159, BD) followed by washing was performed
before the cell lysis. Cells were lysed in the buffer (1 %
Triton-X–100, 10 mM TEA pH 8.2, 150 mM NaCl,
1 mM CaCl2, 1 mM MgCl2) containing a cocktail of
EDTA-free protease inhibitors (Roche Diagnostics) and
immune complexes were precipitated from the lysate
with protA beads (CL-4B, Pharmacia). Immunoprecipi-
tates were reduced in sample buffer (containing 4 % SDS
and 5 % β-mercapto-ethanol), heated for 5 min at 95 °C,
run on a 7 % polyacrylamide gel (SDS-PAGE) and trans-
ferred onto nitrocellulose membrane. Nitrocellulose mem-
branes were incubated in blocking buffer (tris-buffered
saline containing 0.1 % Tween 20 and 4 % BSA) and
incubated overnight at 4 °C with the specified primary
antibody or DC-SIGN-Fc diluted according to the manu-
facturer. Membranes were incubated with appropriate
horseradish peroxidase conjugated secondary antibodies
for 2 h and developed using the enhanced chemilumines-
cence detection system (Amersham, Buckinghamshire,
UK).
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Alternatively, the PBLs were surface biotinylated with
sulfo-NHS-biotin (Pierce, Rockford, IL), and subse-
quently lysed. CD56 and DC-SIGN ligands were immune
precipitated from lysates in specific buffers. All following
procedures were carried out as described above but the
membranes were stained with peroxidase-conjugated
streptavidin (Vector, Burlingame, CA).
Cytotoxicity assay
The lactate dehydrogenase (LDH)-based CytoTox 96
Assay (Promega) was used to determine in vitro cytotox-
icity according to the manufacturer’s instructions. Briefly,
the culture medium was changed to Opti-MEM supplied
with 3 % heat-inactivated FCS for experimental cells
immediately before the experiment following the extensive
washing to avoid contamination with LDH from FCS.
4 × 104 DCs (target cells)/sample, in quadruplicate were
co-cultured with 2 × 105 isolated CD56pos cells (min 90 %
purity). Alternatively: 1) DCs were preincubated with anti-
DC-SIGN mAbs (to 30 μg/ml) for 30 min and cytotoxicity
was performed in the medium containing these anti-
bodies; 2) CD56pos cells were preincubated for 4 h with
the C3d peptide blocking NCAM homotypic interaction.
After 4 h of incubation for each different experimental
condition, released LDH into the culture supernatants
was measured with a 30-min coupled enzymatic assay,
which results in the conversion of a tetrazolium salt into a
red formazan product that is read at 490 nm in an auto-
mated plate reader (Bio-Rad).
Flow cytometry
Analytical flow cytometry was performed on FACS calibur
(BD Pharmingen). Data analysis and graphics were ac-
quired using the WinMDI 2.1 software package (http://
facs.scripps.edu/software.html).
Anion exchange chromatography (AEX)
Activated and cultured in the presence of IL-2 PBLs
were washed with PBS and incubated with anti-CD56
mAbs (clone B159, BD Biosciences). Cells were lysed in
the presence of 1 % NP-40 and cell surface CD56 was
immuneprecipitated with protA beads (CL-4B, Pharma-
cia, Uppsala, Sweden). Immune precipitated complexes
after washing were freed from the beads using 20× vol-
ume 0.1 M glycin-HCL buffer (pH 2.6) for 3 min RT
with shaking. Beads were spinned down with 7000 g for
3 minutes. The supernatant pH was neutralized by add-
ing 0.4 volume of 1 M Trsi-HCl (pH 7.5). Polysialilated
CD56 was separated from weakly non-sialylated CD56
by means of anion exchange chromatography. AEX was
carried out on a Surveyor LC system (Thermofinnigan)
equipped with a strong anion exchange column (Pro-
Sphere polymeric SAX column, 75 × 7.5 mm, 1000A,
10 μ) and a Photo Diode Array detector. Separations
were carried out using linear gradient from 0 to 0.5 M
Ammonium Carbonate in MilliQ (freshly prepared) in
30 minutes at a flow-rate of 1 ml/min. Fraction of 1 ml
were collected and concentrated in a speedvac.
Statistical analysis
Significance was determined with unpaired t test (two
ailed) and indicated in figures with stars. *, p ≤ 0.05;
**, p ≤ 0.005; ***, p ≤ 0.0005. Data are presented as mean
+/− SD (error bars).
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